The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AADi; AstraZeneca Canada; Bristol Myers Squibb Foundation; Ipsen; Pfizer; Seagen; Taiho Oncology
Research Funding - Arcus Biosciences (Inst); ASCO (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb Foundation (Inst); Calithera Biosciences (Inst); Corcept Therapeutics Inc. (Inst); Cue Biopharma (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); Inhibitex Inc. (Inst); Ipsen (Inst); Merck (Inst); PCI Biotech (Inst); Suzhou Transcenta Therapeutics Co. (Inst); SynCore Biotechnology Co. Ltd. (Inst); Syros Pharmaceuticals Inc. (Inst); Taiho Oncology (Inst); Xencor Inc. (Inst)
Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial.
 
Jaume Capdevila
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Eisai; Esteve; Exelixis; Ipsen; Isotopen Technologien; Lilly; Merck Serono; Novartis; Pfizer; Roche/Genentech; Sanofi
Speakers' Bureau - Bayer; Eisai; Esteve; Hutchison MediPharma; Ipsen; Isotopen Technologien; Lilly; Merck Serono; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Gilead Sciences (Inst); Ipsen (Inst); Ipsen (Inst); ITM Solucin (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Eisai; Gilead Sciences; Ipsen; Pfizer
 
Valentina Gambardella
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Amcure (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); FibroGen (Inst); Genentech (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono (Inst); MSD (Inst); Natera (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst); Sierra Oncology (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Yasutoshi Kuboki
Honoraria - Kyowa Kirin; Lilly Japan; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Incyte; Noile-Immune Biotech, Inc; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Carna Biosciences (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Genmab (Inst); Incyte (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Kyowa Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; Chugai Pharma; Incyte
 
Olatunji Alese
No Relationships to Disclose
 
Daniel Morgensztern
Stock and Other Ownership Interests - Abbott Laboratories; Bristol-Myers Squibb/Medarex
Consulting or Advisory Role - Abbvie; Arcus Biosciences; Bayer; Bristol-Myers Squibb/Medarex; G1 Therapeutics; Johnson & Johnson/Janssen; Lilly Medical; Mirati Therapeutics; Natera; Tubulis GmbH
Research Funding - Abbvie (Inst); Altum Pharmaceuticals (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Baxter (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EpicentRx (Inst); Genprex (Inst); Heat Biologics (Inst); Hybercell (Inst); ImmunityBio (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); NeoImmuneTech (Inst); Pfizer (Inst); Roche (Inst); Surface Oncology (Inst); Y-mAbs Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Genprex
 
Cyrus Sayehli
Honoraria - Boehringer Ingelheim France (Inst)
Consulting or Advisory Role - Boehringer Ingelheim
Travel, Accommodations, Expenses - Boehringer Ingelheim; Catalym; Lilly
 
Miguel Sanmamed
Honoraria - Bristol Myers Squibb Foundation; MSD
Consulting or Advisory Role - Catalym; MSD; Numab
Research Funding - Roche (Inst)
 
Edurne Arriola
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; Roche; Sanofi
Speakers' Bureau - AstraZeneca; Bristol Myers Squibb Foundation; MSD Oncology; Roche
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; Takeda
 
Matus Studeny
Employment - Boehringer Ingelheim
 
Mohamed Bouzaggou
Employment - Boehringer Ingelheim
 
Zhiheng Chen
Employment - Boehringer Ingelheim
 
Valeria Lifke
Employment - Boehringer Ingelheim
 
Juergen Wolf
Honoraria - Abbvie; Amgen; Amgen Astellas BioPharma; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; DISCO Pharmaceuticals; Ellipses Pharma; Genmab; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Nuvalent, Inc.; Pfizer; Regeneron; Roche; Seagen; Takeda; Turning Point Therapeutics; Zuelling Pharma
Consulting or Advisory Role - Abbvie; Amgen; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Ignyta; Janssen; Lilly; Loxo/Lilly; Merck; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Roche; Seagen; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Janssen; Novartis; Pfizer
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Janssen; Merck; Mirati Therapeutics; Novartis; Pfizer; Sanofi
 
Martin Wermke
Honoraria - Amgen; BMS GmbH & Co. KG; Boehringer Ingelheim; GWT; Janssen; Lilly; Merck Serono; Merck Serono; Novartis; Pfizer; SYNLAB
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; ImCheck therapeutics; immatics; ISA Pharmaceuticals; Lilly; Novartis; PharmaMar; Regeneron; Tacalyx; Zymeworks
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; GEMoaB; immatics; Iovance Biotherapeutics; Janssen Oncology; Merck Serono; Pfizer; Sanofi/Aventis